These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
754 related articles for article (PubMed ID: 30661449)
1. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7. Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449 [TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 7 agonists: chemical feature based pharmacophore identification and molecular docking studies. Yu H; Jin H; Sun L; Zhang L; Sun G; Wang Z; Yu Y PLoS One; 2013; 8(3):e56514. PubMed ID: 23526932 [TBL] [Abstract][Full Text] [Related]
3. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification. Islam MA; Pillay TS J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527 [TBL] [Abstract][Full Text] [Related]
4. Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation. Kumbhar N; Nimal S; Barale S; Kamble S; Bavi R; Sonawane K; Gacche R Sci Rep; 2022 Feb; 12(1):1712. PubMed ID: 35110603 [TBL] [Abstract][Full Text] [Related]
5. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation. Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125 [TBL] [Abstract][Full Text] [Related]
6. Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors. Kandakatla N; Ramakrishnan G Adv Bioinformatics; 2014; 2014():812148. PubMed ID: 25525429 [TBL] [Abstract][Full Text] [Related]
7. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease. Iqbal S; Anantha Krishnan D; Gunasekaran K J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053 [TBL] [Abstract][Full Text] [Related]
8. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine. Chaudhari HK; Pahelkar A Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898 [TBL] [Abstract][Full Text] [Related]
9. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation. Qiu Y; Zhou L; Hu Y; Bao Y J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691 [TBL] [Abstract][Full Text] [Related]
10. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation. Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817 [TBL] [Abstract][Full Text] [Related]
11. In silico analysis of human Toll-like receptor 7 ligand binding domain. Gupta CL; Akhtar S; Sayyed U; Pathak N; Bajpai P Biotechnol Appl Biochem; 2016 May; 63(3):441-50. PubMed ID: 25817271 [TBL] [Abstract][Full Text] [Related]
12. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach. Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500 [TBL] [Abstract][Full Text] [Related]
13. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex. Mishra V; Pathak C J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849 [TBL] [Abstract][Full Text] [Related]
14. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors. Tripathy S; Azam MA; Jupudi S; Sahu SK J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860 [TBL] [Abstract][Full Text] [Related]
15. Vaghefinezhad N; Farsani SF; Gharaghani S Curr Drug Discov Technol; 2021; 18(1):139-157. PubMed ID: 31721705 [TBL] [Abstract][Full Text] [Related]
16. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches. Jethwa M; Gangopadhyay A; Saha A J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597 [TBL] [Abstract][Full Text] [Related]
17. Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer's disease. Jiang Y; Gao H Phytomedicine; 2019 Feb; 54():278-290. PubMed ID: 30668379 [TBL] [Abstract][Full Text] [Related]
18. Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors. Sakkiah S; Lee KW Acta Pharmacol Sin; 2012 Jul; 33(7):964-78. PubMed ID: 22684028 [TBL] [Abstract][Full Text] [Related]
19. Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling. Kumar R; Son M; Bavi R; Lee Y; Park C; Arulalapperumal V; Cao GP; Kim HH; Suh JK; Kim YS; Kwon YJ; Lee KW Acta Pharmacol Sin; 2015 Aug; 36(8):998-1012. PubMed ID: 26051108 [TBL] [Abstract][Full Text] [Related]
20. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models. Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]